Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs FuelCell Energy Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while FuelCell Energy Inc trades at $21.64 (market cap $1.54B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 19.2× FuelCell Energy Inc's market cap, and FuelCell Energy Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FCEL | |
|---|---|---|
Market Cap | $29.60B | $1.54B |
Sector | Health | Industrials |
52-Week High | $491.22 | $36.01 |
52-Week Low | $205.48 | $3.92 |
Enterprise Value | $27.56B | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
FCEL trades at $22.16, up 11.75% in the past 24 hours, but remains in a bearish technical trend. The company continues to post significant losses, with a net income margin of -132.41% in 2025, despite recent revenue growth to $158.16M. Analyst sentiment is divided with a 45% buy and 45% hold consensus, and a price target of $20.75. Recent news highlights partnerships and volatility within the hydrogen sector.
The outlook is clouded by persistent unprofitability and negative cash flow from operations, posing substantial risk. Upside potential hinges on successful commercialization of technology and sector tailwinds, but the stock faces headwinds from execution challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
